ScholarLens Back to search
2001•Anhui Medical and Pharmaceutical JournalRequires access

A case-control study of lamivudine in the treatment of chronic hepatitis B

Hua Yin

Open publisher page 0 citations

Abstract

AIM To investigate the effect and character of lamivudine in the treatment of patients with chronic hepatitis B. METHODS The effect of lamivudine and (huganpian with dangfeiligannin) on serum ALT, HBeAg, antiHBe and HBV DNA of 32 patients by pair matching was compared. RESULTS Rate of ALT normalization in lamivudine group was slower than in control group, but after 6 months, there was similar in two groups ( P 0 05), HBV DNA response rate in lamivudine group was 53 1%, 78 1% and 84 4% at 1,2 and 6 months of duration treatment respectively, there was significant difference between two groups ( P 0 001), but there was no statistical difference in HBeAg seroconversion rate of two groups. CONCLUSION HBV DNA response rate of lamivudine in the treatment of patients with chronic hepatitis B was higher, descent of ALT was slower, and HBeAg seroconversion rate was low.

About this research paper

What this paper is about

AIM To investigate the effect and character of lamivudine in the treatment of patients with chronic hepatitis B. METHODS The effect of lamivudine and (huganpian with dangfeiligannin) on serum ALT, HBeAg, antiHBe and HBV DNA of 32 patients by pair matching was compared. RESULTS Rate of ALT normalization in lamivudine group was slower than in control group, but after 6 months, there was similar in two groups ( P 0 05), HBV DNA response rate in lamivudine group was 53 1%, 78 1% and 84 4% at 1,2 and 6 months of duration treatment respectively, there was significant difference between two groups ( P 0 001), but there was no statistical difference in HBeAg seroconversion rate of two groups. CONCLUSION HBV DNA response rate of lamivudine in the treatment of patients with chronic hepatitis B was higher, descent of ALT was slower, and HBeAg seroconversion rate was low.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

AIM To investigate the effect and character of lamivudine in the treatment of patients with chronic hepatitis B. METHODS The effect of lamivudine and (huganpian with dangfeiligannin) on serum ALT, HBeAg, antiHBe and HBV DNA of 32 patients by pair matching was compared. RESULTS Rate of ALT normalization in lamivudine group was slower than in control group, but after 6 months, there was similar in two groups ( P 0 05), HBV DNA response rate in lamivudine group was 53 1%, 78 1% and 84 4% at 1,2 and 6 months of duration treatment respectively, there was significant difference between two groups ( P 0 001), but there was no statistical difference in HBeAg seroconversion rate of two groups. CONCLUSION HBV DNA response rate of lamivudine in the treatment of patients with chronic hepatitis B was higher, descent of ALT was slower, and HBeAg seroconversion rate was low.

Key concepts: Lamivudine, Medicine, Seroconversion, Chronic hepatitis, HBeAg, Gastroenterology, Internal medicine, Hepatitis B

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
A case-control study of lamivudine in the treatment of chronic hepatitis B — Research Paper | ScholarLens